Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a new MRI scan spot prostate cancer better?

NCT ID NCT07249281

Diagnosis Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of MRI scan to see if it can diagnose prostate cancer more accurately than standard MRI. Researchers will compare the new scan's results with tissue samples from biopsies or surgery. The goal is to find better ways to detect cancer without unnecessary procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MRI scan
What this could lead to
If successful, this could lead to a more accurate, non-invasive way to diagnose prostate cancer, reducing unnecessary biopsies.
What could go wrong
This is an early-stage diagnostic study, not a treatment trial. The new MRI method may not prove significantly better than current techniques.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2020

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Men with clinical suspicion of prostate cancer will be recruited from six participating hospitals. Clinical suspicion may be based on elevated prostate-specific antigen (PSA) levels, abnormal digital rectal examination, or other clinical findings. All participants will undergo prostate MRI including TDDMRI. Histopathological confirmation through biopsy or prostatectomy will be obtained in a subset of participants who consent to tissue sampling. The study population will therefore include both histopathology-positive and -negative cases, enabling evaluation of diagnostic performance and development of imaging-based diagnostic criteria.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical suspicion of prostate cancer (elevated PSA, abnormal digital rectal examination, or other clinical indication). * Undergoing prostate MRI including TDDMRI as part of diagnostic evaluation. Able and willing to provide written informed consent. Exclusion Criteria: * Contraindications to MRI (e.g., pacemaker, ferromagnetic implants, severe claustrophobia). * Prior treatment for prostate cancer (surgery, radiation, hormonal therapy, chemotherapy). * Severe comorbid conditions precluding MRI or biopsy. * Inability to provide informed consent. * Poor image quality due to motion or technical artifacts (assessed at imaging QC).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffusion mri are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diffusion mri Prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

  • Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University

    COMPLETED

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Dalian Medical University

    RECRUITING

    Dalian, Liaoning, China

  • The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital)

    RECRUITING

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310000, China

  • Zhejiang Hospital

    RECRUITING

    Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.